查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726374

全球抗凝血劑市場：市場規模、佔有率、趨勢分析（按藥物類別、給藥途徑、應用和地區）、細分市場預測（2025-2030 年）

Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

抗凝血劑市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球抗凝血劑市場規模預計到2030年將達到471億美元，2025年至2030年期間的複合年成長率為4.8%。

市場發展的主要動力是心血管疾病（CVD）盛行率的上升和人口老化。根據世界衛生組織統計，2019年，心血管疾病是全球死亡的主要原因，造成1,790萬人死亡，佔全球死亡人數的32%。其中，85%是由於心臟病發作和中風引起的。此外，在1,700萬因非傳染性疾病而過早死亡的人口中，有38%是因心血管疾病而死亡。

此外，久坐的生活方式是導致全球因缺乏運動而血栓增加的主要原因，從而增加了對抗凝劑的需求。缺乏運動會增加靜脈血栓栓塞症（VTE）的風險，包括肺動脈栓塞（PE）和深層靜脈栓塞症（DVT）。當腿部深層靜脈形成血栓時就會發生 DVT，而當血栓從深層靜脈流向肺部時就會發生 PE。根據美國國家醫學圖書館的數據，VTE（包括 DVT 和 PE）每年在美國影響約 90 萬人。這次災難導致數十萬人住院，約30萬人死亡。預計靜脈血栓栓塞症 (VTE) 盛行率的上升和對有效治療方案的需求的增加將推動市場的發展。

此外，它還透過促進技術創新、提高抗凝血治療的有效性和安全性以及改善患者監測和結果，在振興抗凝血劑市場方面發揮重要作用。藥物發現和開發的進步已經產生了具有改良特性的新型抗凝血劑，例如半衰期更長、與其他藥物的相互作用更少、出血風險更低。這些新型抗凝血劑為患者提供了更多的治療選擇和更好的治療效果。根據美國國立衛生研究院介紹，基因療法是一種治療血栓的新方法，它利用基因來糾正導致血栓的潛在基因缺陷。儘管這種方法仍處於發展的早期階段，但它有可能成為一種有效的血栓治療方法。例如，2022年11月，FDA核准了基因治療藥物Hemgenix，用於使用預防性IX因子療法治療反覆出現嚴重出血事件的B型血友病成年患者。這是一種一次性基因療法，將凝血因子 IX 的基因注入肝臟。

抗凝血劑市場報告重點

  • 根據藥物類別，新型口服抗凝血劑 (NOAC) 部分將在全球抗凝血劑產業中佔據主導地位，到 2024 年的收入佔有率將達到 57.2%。預計肝素部分在預測期內將大幅增加。
  • 2024 年，口服抗凝血劑佔據全球抗凝血劑產業的最大收益佔有率。根據給藥途徑，預計注射抗凝血劑領域將在 2025 年至 2030 年間實現成長。
  • 2024 年，心房顫動/心肌梗塞（心臟病發作）領域佔據了全球抗凝血劑產業的主導地位。預計深層靜脈栓塞症(DVT) 在預測期內將顯著成長。
  • 到 2024 年，北美將在全球抗凝血劑產業佔據主導地位，收入佔有率將達到 51.2%。預計在預測期內，亞太抗凝血劑市場將以 6.1% 的最快複合年成長率成長。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章抗凝血劑市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 抗凝血劑市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章抗凝血劑市場：按藥物類別的估計和趨勢分析

  • 藥品類別儀表板
  • 抗凝血劑市場：依藥物類別進行差異分析
  • 全球抗凝血劑市場規模及趨勢分析（依藥物類別）（2018-2030）
  • 新型口服抗凝血藥物（NOAC）
    • Elixir
    • 拜瑞妥
    • 薩瓦伊薩和利克西亞娜
    • 帕達克薩
  • 維生素K拮抗劑
  • 直接凝血酶抑制劑
  • 肝素
    • 種類
    • 原料

第5章抗凝血劑市場：依給藥途徑的估計與趨勢分析

  • 給藥途徑儀表板
  • 抗凝血劑市場：按給藥途徑進行的變化分析
  • 全球抗凝血劑市場規模及給藥途徑趨勢分析（2018-2030）
  • 口服抗凝血藥
  • 注射用抗凝血劑

第6章抗凝血劑市場：按應用的估計和趨勢分析

  • 用於特定目的的儀表板
  • 抗凝血劑市場：按應用進行差異分析
  • 全球抗凝血劑市場規模及應用趨勢分析（2018-2030）
  • 心房顫動/心肌梗塞（心臟病發作）
  • 深層靜脈栓塞症（DVT）
  • 肺動脈栓塞
  • 其他用途

第7章抗凝血劑市場：按地區估計和趨勢分析

  • 市場儀表板：按地區
  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 抗凝血劑市場：按地區分類的要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要企業熱力圖分析（2024年）
  • 公司簡介
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market size is expected to reach USD 47.10 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Heparin segment is projected to experience significant growth over the forecast period.
  • Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030.
  • The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period.
  • North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. Asia Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug category outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Segment Dashboard
  • 4.2. Anticoagulants Market: Drug Category Movement Analysis
  • 4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2018 to 2030 (USD Million)
  • 4.4. Novel Oral Anticoagulants (NOACs)
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Eliquis
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Xarelto
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Savaysa & lixiana
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Pradaxa
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Vitamin K Antagonist
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Direct Thrombin Inhibitors
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Heparin
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Type
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.2. Low Molecular Weight Heparin
        • 4.7.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.3. Ultra-low Molecular Weight Heparin
        • 4.7.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.4. Unfractionated Heparin
        • 4.7.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Source
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.2. Porcine
        • 4.7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.3. Bovine
        • 4.7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.4. Others
        • 4.7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Anticoagulants Market: Route of Administration Movement Analysis
  • 5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Anticoagulants
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Anticoagulants
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Anticoagulants Market: Application Movement Analysis
  • 6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.5. Deep Vein Thrombosis (DVT)
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.6. Pulmonary Embolism
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.7. Other Applications
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. China
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Aspen Holdings
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bristol-Myers Squibb Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Eisai Co., Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 Global anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 8 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 11 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 Europe anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 21 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 23 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 24 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 27 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 29 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 30 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 32 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 33 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 35 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 36 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 42 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 43 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 46 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 48 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 49 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 52 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 55 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 57 Latin America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 58 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 59 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 61 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 62 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Brazil surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 64 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 65 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Argentina surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 67 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 68 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 71 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 72 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 77 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 78 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Anticoagulants market: market outlook
  • Fig. 10 Anticoagulants competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Anticoagulants market driver impact
  • Fig. 16 Anticoagulants market restraint impact
  • Fig. 17 Anticoagulants market strategic initiatives analysis
  • Fig. 18 Anticoagulants market: Drug category movement analysis
  • Fig. 19 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 21 Eliquis market estimates and forecast, 2018 - 2030
  • Fig. 22 Xarelto market estimates and forecast, 2018 - 2030
  • Fig. 23 Savaysa & lixiana market estimates and forecast, 2018 - 2030
  • Fig. 24 Pradaxa market estimates and forecast, 2018 - 2030
  • Fig. 25 Vitamin K Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 26 Direct Thrombin Inhibitors market estimates and forecast, 2018 - 2030
  • Fig. 27 Heparin market estimates and forecast, 2018 - 2030
  • Fig. 28 Low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 29 Ultra-low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 30 Unrationed heparin market estimates and forecast, 2018 - 2030
  • Fig. 31 Heparin sources market estimates and forecast, 2018 - 2030
  • Fig. 32 Porcine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 33 Bovine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 34 Other heparin market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 37 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 38 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 39 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 40 Anticoagulants market: Application movement analysis
  • Fig. 41 Anticoagulants market: Application outlook and key takeaways
  • Fig. 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 44 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 45 Other applications market estimates and forecasts,2018 - 2030
  • Fig. 46 Global anticoagulants market: Regional movement analysis
  • Fig. 47 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 55 France market estimates and forecasts, 2018 - 2030
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 59 China market estimates and forecasts, 2018 - 2030
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 61 India market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030